As this happened, Maxim Group initiated its Oncolytics Biotech, Inc [ONCY] rating to a Buy in a research note published on October 06, 2022; the price target was $3. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating.
Price Performance Review of ONCY
On Friday, Oncolytics Biotech, Inc [NASDAQ:ONCY] saw its stock fall -5.66% to $0.79. Over the last five days, the stock has lost -9.04%. Oncolytics Biotech, Inc shares have fallen nearly -13.44% since the year began. Nevertheless, the stocks have fallen -34.08% over the past one year. While a 52-week high of $1.53 was reached on 01/06/25, a 52-week low of $0.71 was recorded on 01/15/25. SMA at 50 days reached $0.9278, while 200 days put it at $1.0274.
Levels Of Support And Resistance For ONCY Stock
The 24-hour chart illustrates a support level at 0.7723, which if violated will result in even more drops to 0.7536. On the upside, there is a resistance level at 0.8198. A further resistance level may holdings at 0.8486. The Relative Strength Index (RSI) on the 14-day chart is 38.05, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0692, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 79.67%. Stochastics %K at 26.83% indicates the stock is a holding.
How much short interest is there in Oncolytics Biotech, Inc?
A steep rise in short interest was recorded in Oncolytics Biotech, Inc stocks on 2024-10-31, growing by 1.79 million shares to a total of 2.81 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 1.02 million shares. There was a rise of 63.79%, which implies that there is a positive sentiment for the stock.
